Source:http://linkedlifedata.com/resource/pubmed/id/10700190
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2000-4-7
|
| pubmed:abstractText |
The early development of blood vessels consists of two phases, vasculogenesis and angiogenesis, which involve distinct and also overlapping molecular regulators, but the intracellular signal transduction pathways involved in these processes have not been well defined. We disrupted Map3k3 (also known as Mekk3), which encodes Mekk3, a member of the Mekk/Ste11 family, in mice. Map3k3-/- embryos died at approximately embryonic day (E) 11, displaying disruption of blood vessel development and the structural integrity of the yolk sac. Angiogenesis was blocked at approximately E9.5 in mutant embryos. Map3k3 disruption did not alter the expression of the genes encoding Vegf-1, angiopoietin or their receptors. The development of embryonic, but not maternal, blood vessels in the placentas of Map3k3-/- embryos was impaired, revealing an intrinsic defect in Map3k3-/- endothelial cells. Moreover, Mekk3 activated myocyte-specific enhancer factor 2C (Mef2c), a transcription factor crucial for early embryonic cardiovascular development through the p38 mitogen-activated protein kinase (Mapk) cascade. We conclude that Mekk3 is necessary for blood vessel development and may be a possible target for drugs that control angiogenesis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Fetal Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/MAP Kinase Kinase Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/MAP Kinase Kinase Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1061-4036
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
309-13
|
| pubmed:dateRevised |
2011-11-2
|
| pubmed:meshHeading |
pubmed-meshheading:10700190-Animals,
pubmed-meshheading:10700190-Blood Vessels,
pubmed-meshheading:10700190-Embryonic and Fetal Development,
pubmed-meshheading:10700190-Fetal Heart,
pubmed-meshheading:10700190-Fetal Proteins,
pubmed-meshheading:10700190-Genes, Lethal,
pubmed-meshheading:10700190-Genotype,
pubmed-meshheading:10700190-Gestational Age,
pubmed-meshheading:10700190-MAP Kinase Kinase Kinase 3,
pubmed-meshheading:10700190-MAP Kinase Kinase Kinases,
pubmed-meshheading:10700190-Mice,
pubmed-meshheading:10700190-Mice, Knockout,
pubmed-meshheading:10700190-Morphogenesis,
pubmed-meshheading:10700190-Neovascularization, Physiologic,
pubmed-meshheading:10700190-Phenotype,
pubmed-meshheading:10700190-Polymerase Chain Reaction,
pubmed-meshheading:10700190-Recombinant Fusion Proteins,
pubmed-meshheading:10700190-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:10700190-Transfection,
pubmed-meshheading:10700190-Yolk Sac
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Mekk3 is essential for early embryonic cardiovascular development.
|
| pubmed:affiliation |
Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|